Jenny Howell appointed Chief Operating Officer

Jenny Howell joins Thirty Group as Chief Operating Officer. Jenny has more than 20 years’ experience in the biotech and pharmaceutical industry, most recently with AstraZeneca/MedImmune where she held a number of senior leadership positions including Chief of Staff to...

DR. JOHN EFTHIMIOU APPOINTED CHIEF MEDICAL OFFICER

John Efthimiou BSc MD FRCP is a respiratory specialist physician/scientist trained in London and Oxford teaching hospitals, accredited in both Respiratory and General Medicine. He joined Thirty Group in June 2019 and has over 25 years’ experience in and advising large...

MORNINGSIDE VENTURES INVESTS IN THIRTY HOLDINGS

Thirty Holdings Limited completed a £25 million equity investment led by Morningside Ventures, a major investor in the global Life Science sector. The investment enables the Group to accelerate research and development. We are delighted to welcome Isaac Cheng to the...

A NEW NAME FOR A NEW ERA

Thirty Holdings Limited established following a corporate restructure. The Company trading name will be 30 Technology with the name derived from the molecular weight of nitric oxide (30). Edixomed Limited is now a wholly owned subsidiary of Thirty Holdings, focusing...